Genomic predictors of prostate cancer therapy outcomes

Expert Review of Molecular Diagnostics
Daniel J LewinshteinPeter S Nelson

Abstract

Although numerous attempts have been made to forecast outcomes for prostate cancer after therapy using clinical and histological variables, the ability to accurately predict an individual's response to a specific treatment remains elusive. Recently, major advances in the field of genomics have made possible the near-comprehensive assessment of the genetic status of tumor genomes, with major concentration on predicting an individual's response to a specific treatment. Genomic approaches to treatment response include, but are not limited to, detection of gene rearrangements, DNA copy-number aberrations, single-nucleotide polymorphisms, epigenetic changes and differential gene-expression patterns. These approaches have been used to predict response to treatment for local and systemic disease in multiple small cohorts. Further study with larger cohorts and longer follow-up should result in more concordance among genomic approaches, and will enable physicians to gain insight into the heterogeneity of supposedly 'similar' cancers and help tailor treatments accordingly.

References

Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S L TuckerH D Thames
Sep 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·R K MoyzisJ R Wu
Mar 1, 1967·Journal of Clinical Pathology·J A Fleming, J W Stewart
Nov 1, 1994·Genes, Chromosomes & Cancer·H SchmittH Scherthan
Nov 22, 1994·Proceedings of the National Academy of Sciences of the United States of America·W H LeeW G Nelson
Aug 19, 1997·Proceedings of the National Academy of Sciences of the United States of America·M P MyersN K Tonks
May 30, 1998·Journal of the National Cancer Institute·M W KattanP T Scardino
Aug 27, 1998·Journal of the National Cancer Institute·T R RebbeckS B Malkowicz
Oct 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J ZelefskyS A Leibel
Mar 17, 1999·Proceedings of the National Academy of Sciences of the United States of America·Y PekarskyC M Croce
May 11, 1999·JAMA : the Journal of the American Medical Association·C R PoundP C Walsh
May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M W KattanP T Scardino
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A V D'AmicoC N Coleman
Oct 19, 1999·The Journal of Urology·L DonaldsonJ Griffith
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W K Oh, P W Kantoff
Dec 10, 1999·The New England Journal of Medicine·M A Eisenberger, P C Walsh
Mar 8, 2000·The Oncologist·G AuclercD Khayat
Jun 22, 2000·Human Mutation·E AlgarP Smith
Oct 3, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M W KattanS A Leibel
Mar 17, 2001·Nature Reviews. Molecular Cell Biology·Y Yarden, M X Sliwkowski
Aug 24, 2001·Nature·S M DhanasekaranA M Chinnaiyan
Mar 20, 2002·Nature Reviews. Cancer·B J Feldman, D Feldman
Mar 21, 2002·Nature Reviews. Cancer·J D Rowley
Jun 28, 2002·Cancer Cell·Dinesh SinghWilliam R Sellers
Sep 5, 2002·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Claudio FiorinoAnna Piazzolla
Sep 13, 2002·The New England Journal of Medicine·Lars HolmbergUNKNOWN Scandinavian Prostatic Cancer Group Study Number 4
Oct 11, 2002·Nature·Sooryanarayana VaramballyArul M Chinnaiyan
Nov 16, 2002·Proceedings of the National Academy of Sciences of the United States of America·George Adrian CalinCarlo M Croce
Dec 31, 2002·International Journal of Radiation Oncology, Biology, Physics·Derek B ChismGerald E Hanks
Mar 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A PollackW U Shipley

❮ Previous
Next ❯

Citations

Mar 13, 2013·Current Opinion in Urology·Michael J Donovan, Carlos Cordon-Cardo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.